Skip to content
BioLegacy Research
  • Services
    • col1
      • In Vitro Services
      • Pharmacology Services
      • Toxicology Services
    • col2
      • IND Process
      • Disease Models
      • Medical Device Testing
    • col3
      • Custom Services
      • Vivarium Space
      • Drug Development Process
      • Histology Services
  • About Us
  • News
  • Animal Species
  • Why BioLegacy
  • Request A Quote
  • Partnering
  • Contact
    • Careers

Uncategorized

FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury

November 14, 2025 | 0

The U.S. Food and Drug Administration today announced it is taking action to approve new labeling submitted by the company that includes the addition of a Boxed Warning, the agency’s most prominent safety warning, to Elevidys (delandistrogene moxeparvovec-rokl), and that the indication section of th Source: FDA Press Releases

Read More

Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research

November 11, 2025 | 0

The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) today announced that Richard Pazdur, M.D., has been appointed director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA. Source: FDA Press Releases

Read More

HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy

November 10, 2025 | 0

The U.S. Department of Health and Human Services (HHS) today announced historic action to restore gold-standard science to women’s health. Source: FDA Press Releases

Read More

FDA Awards Second Batch of National Priority Vouchers

November 6, 2025 | 0

The U.S. Food and Drug Administration today announced six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program. Source: FDA Press Releases

Read More

FDA Warns Companies Over Illegal Marketing of Botox and Related Products

November 5, 2025 | 0

The U.S. Food and Drug Administration issued 18 warning letters to owners of websites illegally marketing unapproved and misbranded botulinum toxin products, commonly called Botox. Source: FDA Press Releases

Read More

FDA Acts to Protect Children from Unapproved Fluoride Drug Products

October 31, 2025

The U.S. Food and Drug Administration today announced actions to restrict the sale of unapproved ingestible fluoride prescription drug products for children. Source: FDA Press Releases

Read More

FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs

October 29, 2025

The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases. Source: FDA Press Releases

Read More

FDA Issues Emergency Use Authorization for New World Screwworm Drug for Dogs

October 24, 2025

FDA issued an Emergency Use Authorization (EUA) concluding that based on the scientific evidence available, Credelio (lotilaner) chewable tablets may be effective in treating New World screwworm (NWS) infestations in dogs and puppies. Source: FDA Press Releases

Read More

FDA Publishes Filing Checklists to Prevent Submission Delays

October 23, 2025

The U.S. Food and Drug Administration today made public filing checklists used internally by Center for Drug Evaluation and Research (CDER) staff to determine if a submitted application is complete and reviewable. Source: FDA Press Releases

Read More

FDA Awards First-Ever National Priority Vouchers to Nine Sponsors

October 16, 2025

The U.S. Food and Drug Administration today announced 9 voucher recipients under the new Commissioner’s National Priority Voucher (CNPV) pilot program. Source: FDA Press Releases

Read More
Older Posts »

Recent Posts

  • FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury
  • Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research
  • HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy
  • FDA Awards Second Batch of National Priority Vouchers
  • FDA Warns Companies Over Illegal Marketing of Botox and Related Products

Archives

  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • October 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • February 2015
  • November 2014
  • May 2014
  • April 2014

Categories

  • BioPharma
  • BTS News
  • Devices & Diagnostics Letter
  • Drug GMP Report
  • Drug Industry Daily
  • FDAnews Device Daily Bulletin
  • FDAnews Drug Daily Bulletin
  • Generic Line
  • International Medical Device Regulatory Monitor
  • International Pharmaceutical Regulatory Monitor
  • News
  • QMN Weekly Bulletin
  • The Food & Drug Letter
  • The GMP Letter
  • Uncategorized
  • Washington Drug Letter

Company

BioLegacy Research
Toll Free: (866) 599-3019
Fax: (858) 605-5916
Email: info@biolegacyresearch.com

PARTNERING

Strategic collaborations are an important part of BioLegacy Research’s growth. Read More >>

CAREERS

To inquire about careers with BioLegacy Research. Read More >>
  • Services
  • Animal Species
  • About Us
  • Why BioLegacy
  • Request A Quote
  • Contact

Follow Us

Attribution

icons created by Freepik – Flaticon

© 2025 BioLegacy Research
Scroll To Top